173 related articles for article (PubMed ID: 32054411)
21. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
22. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
[TBL] [Abstract][Full Text] [Related]
23. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
24. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib-induced acute kidney injury via interstitial nephritis.
Markóth C; File I; Szász R; Bidiga L; Balla J; Mátyus J
Ren Fail; 2021 Dec; 43(1):335-339. PubMed ID: 33567947
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
27. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
28. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Li A; Ambruso SL; Oto OA; Barry M; Edelstein CL
BMC Nephrol; 2022 Jul; 23(1):264. PubMed ID: 35870899
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
30. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
31. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
32. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
33. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
[No Abstract] [Full Text] [Related]
34. Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
Shulman K; Kazarin O; Tannous E; Sofer O
Isr Med Assoc J; 2021 Jun; 23(6):385-386. PubMed ID: 34155856
[No Abstract] [Full Text] [Related]
35. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
36. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
[TBL] [Abstract][Full Text] [Related]
37. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Mehraban Far P; Rullo J; Farmer J; Urton T
Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
39. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies.
Tham K; Prelewicz S; deHoll S; Stephens DM; Gomez CA
Am J Health Syst Pharm; 2024 Feb; 81(4):112-119. PubMed ID: 37675967
[TBL] [Abstract][Full Text] [Related]
40. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations.
Tambaro FP; Wierda WG
Lancet Haematol; 2020 Feb; 7(2):e168-e176. PubMed ID: 32004486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
